Founder of DNAlysis Biotechnology, developer of genetic testing portfolios now used in over 90 countries to advance personalised medicine.

Dr. Danny Meyersfeld earned his PhD from the University of Witwatersrand, South Africa, in 2005. Following two years of post-doctoral research, he founded DNAlysis Biotechnology, driven by a profound interest in advancing personalised medicine.

His vision was inspired by the transformative potential of the Human Genome Project and the opportunity to integrate genomic insights into clinical practice on a global scale.

Recognizing the gap between academic research and its practical application in healthcare, Dr. Meyersfeld focused his efforts on Nutrigenetics—a field that leverages genetic information to personalise nutrition and encourage behavioral change based on validated scientific evidence.

At the time, many international nutrigenetic testing companies faced criticism for relying on questionable science and failing to engage physicians effectively, which led to scepticism within the medical community.

Dr. Meyersfeld adopted a distinct approach to nutrigenetic testing, emphasizing scientific rigor and the ethical integration of genetic insights into clinical care. His strategy included prioritizing clinician education and support to ensure healthcare professionals were equipped to responsibly utilize genetic testing for improved patient outcomes.

Under his leadership, DNAlysis Biotechnology has trained and supported thousands of healthcare providers worldwide, fostering trust and credibility in the field.

The company’s portfolio of tests is designed to be scientifically robust, user-friendly, and accessible, facilitating the seamless incorporation of genetic data into routine medical practice.

DNAlysis Biotechnology’s solutions are now available in over 90 countries, with reports offered in 12 local languages, reflecting its global impact and commitment to enhancing patient care through personalised medicine.